Search Results - "BARDELLI, A"

The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer by Mauri, G., Arena, S., Siena, S., Bardelli, A., Sartore-Bianchi, A.

“…Colorectal cancer (CRC) represents a major cause of cancer deaths worldwide. Although significant progress has been made by molecular and immune therapeutic…”
Get full text

Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer by Siena, S., Sartore-Bianchi, A., Marsoni, S., Hurwitz, H.I., McCall, S.J., Penault-Llorca, F., Srock, S., Bardelli, A., Trusolino, L.

“…Human epidermal growth factor receptor 2 (HER2) is an oncogenic driver, and a well-established therapeutic target in breast and gastric cancers. Using…”
Get full text

How liquid biopsies can change clinical practice in oncology by Siravegna, G., Mussolin, B., Venesio, T., Marsoni, S., Seoane, J., Dive, C., Papadopoulos, N., Kopetz, S., Corcoran, R.B., Siu, L.L., Bardelli, A.

“…Cell-free DNA fragments are shed into the bloodstream by tumor cells. The analysis of circulating tumor DNA (ctDNA), commonly known as liquid biopsy, can be…”
Get full text

Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases by Seoane, J., De Mattos-Arruda, L., Le Rhun, E., Bardelli, A., Weller, M.

“…Challenges in obtaining tissue specimens from patients with brain tumours limit the diagnosis and molecular characterisation and impair the development of…”
Get full text

23: Mutations and acquired resistance in colorectal cancer by Bardelli, A

Get full text

Failure is not final: ctDNA-guided rechallenge therapy in colorectal cancer by Siravegna, G., Bardelli, A.

Get full text

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer by Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J.H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., Ciardiello, F., D'Hoore, A., Diaz-Rubio, E., Douillard, J.-Y., Ducreux, M., Falcone, A., Grothey, A., Gruenberger, T., Haustermans, K., Heinemann, V., Hoff, P., Köhne, C.-H., Labianca, R., Laurent-Puig, P., Ma, B., Maughan, T., Muro, K., Normanno, N., Österlund, P., Oyen, W.J.G., Papamichael, D., Pentheroudakis, G., Pfeiffer, P., Price, T.J., Punt, C., Ricke, J., Roth, A., Salazar, R., Scheithauer, W., Schmoll, H.J., Tabernero, J., Taïeb, J., Tejpar, S., Wasan, H., Yoshino, T., Zaanan, A., Arnold, D.

“…Colorectal cancer (CRC) is one of the most common malignancies in Western countries. Over the last 20 years, and the last decade in particular, the clinical…”
Get full text

Failure is not final: ctDNA-guided rechallenge therapy in colorectal cancer by Siravegna, G., Bardelli, A.

Get full text

Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer by Siena, S., Sartore-Bianchi, A., Garcia-Carbonero, R., Karthaus, M., Smith, D., Tabernero, J., Van Cutsem, E., Guan, X., Boedigheimer, M., Ang, A., Twomey, B., Bach, B.A., Jung, A.S., Bardelli, A.

“…Mutations in rat sarcoma (RAS) genes may be a mechanism of secondary resistance in epidermal growth factor receptor inhibitor-treated patients. Tumor-tissue…”
Get full text

DNA repair-dependent immunogenic liabilities in colorectal cancer: opportunities from errors by Amodio, V., Vitiello, P. P., Bardelli, A., Germano, G.

“…Colorectal cancer (CRC) remains one of the major causes of cancer death worldwide. Chemotherapy continues to serve as the primary treatment modality, while…”
Get full text

24 The Role of KRAS/BRAF Mutations on Response and Resistance to Anti EGFR Therapies in Colorectal Tumors by Bardelli, A

Get full text

Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer by Barault, L., Amatu, A., Bleeker, F.E., Moutinho, C., Falcomatà, C., Fiano, V., Cassingena, A., Siravegna, G., Milione, M., Cassoni, P., De Braud, F., Rudà, R., Soffietti, R., Venesio, T., Bardelli, A., Wesseling, P., de Witt Hamer, P., Pietrantonio, F., Siena, S., Esteller, M., Sartore-Bianchi, A., Di Nicolantonio, F.

“…O6-methyl-guanine-methyl-transferase (MGMT) silencing by promoter methylation may identify cancer patients responding to the alkylating agents dacarbazine or…”
Get full text

Use of a Dual mobility cup to prevent hip early arthroplasty dislocation in patients at high falls risk by Nonne, D., Sanna, F., Bardelli, A., Milano, P., Rivera, F.

“…•Hip fracture is a common serious injury that occurs mainly in older people and Dual mobility hip arthroplasty or emiarthroplasty for its treatment remains a…”
Get full text

Liquid biopsies to evaluate early therapeutic response in colorectal cancer by Montagut, C., Siravegna, G., Bardelli, A.

Get full text

Consensus on precision medicine for metastatic cancers: a report from the MAP conference by Swanton, C., Soria, J.-C., Bardelli, A., Biankin, A., Caldas, C., Chandarlapaty, S., de Koning, L., Dive, C., Feunteun, J., Leung, S.-Y., Marais, R., Mardis, E.R., McGranahan, N., Middleton, G., Quezada, S.A., Rodón, J., Rosenfeld, N., Sotiriou, C., André, F.

“…Recent advances in biotechnologies have led to the development of multiplex genomic and proteomic analyses for clinical use. Nevertheless, guidelines are…”
Get full text

RET fusions in a small subset of advanced colorectal cancers at risk of being neglected by Pietrantonio, F., Di Nicolantonio, F., Schrock, A.B., Lee, J., Morano, F., Fucà, G., Nikolinakos, P., Drilon, A., Hechtman, J.F., Christiansen, J., Gowen, K., Frampton, G.M., Gasparini, P., Rossini, D., Gigliotti, C., Kim, S.T., Prisciandaro, M., Hodgson, J., Zaniboni, A., Chiu, V.K., Milione, M., Patel, R., Miller, V., Bardelli, A., Novara, L., Wang, L., Pupa, S.M., Sozzi, G., Ross, J., Di Bartolomeo, M., Bertotti, A., Ali, S., Trusolino, L., Falcone, A., de Braud, F., Cremolini, C.

“…Recognition of rare molecular subgroups is a challenge for precision oncology and may lead to tissue-agnostic approval of targeted agents. Here we aimed to…”
Get full text

Review: Peering through a keyhole: liquid biopsy in primary and metastatic central nervous system tumours by Bertero, L., Siravegna, G., Rudà, R., Soffietti, R., Bardelli, A., Cassoni, P.

“…Tumour molecular profiling by liquid biopsy is being investigated for a wide range of research and clinical purposes. The possibility of repeatedly…”
Get full text

Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer by Amatu, A., Barault, L., Moutinho, C., Cassingena, A., Bencardino, K., Ghezzi, S., Palmeri, L., Bonazzina, E., Tosi, F., Ricotta, R., Cipani, T., Crivori, P., Gatto, R., Chirico, G., Marrapese, G., Truini, M., Bardelli, A., Esteller, M., Di Nicolantonio, F., Sartore-Bianchi, A., Siena, S.

“…Objective response to dacarbazine, the intravenous form of temozolomide (TMZ), in metastatic colorectal cancer (mCRC) is confined to tumors harboring…”
Get full text

Tracking colorectal cancer evolution in time and space by Rospo, G., Corti, G., Crisafulli, G., Novara, L., Bardelli, A.

Get full text

Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor by Siravegna, G, Sartore-Bianchi, A, Mussolin, B, Cassingena, A, Amatu, A, Novara, L, Buscarino, M, Corti, G, Crisafulli, G, Bartolini, A, Tosi, F, Erlander, M, Di Nicolantonio, F, Siena, S, Bardelli, A

“…Monitoring response and resistance to kinase inhibitors is essential to precision cancer medicine, and is usually investigated by molecular profiling of a…”
Get full text